These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 30592371

  • 1. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
    Cillo U, Saracino L, Vitale A, Bertacco A, Salizzoni M, Lupo F, Colledan M, Corno V, Rossi G, Reggiani P, Baccarani U, Bresàdola V, De Carlis L, Mangoni I, Ramirez Morales R, Agnes S, Nure E.
    Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
    [Abstract] [Full Text] [Related]

  • 2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 3. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Duvoux C, Nevens F, Fung JJ, Dong G, Rauer B, Junge G, H2304 Study Group.
    Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
    [Abstract] [Full Text] [Related]

  • 4. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC, Brown RS, Chavin KD, Sudan D, Koneru B, Junge G, Dong G, Patel D, Teperman L, Fung JJ.
    Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
    [Abstract] [Full Text] [Related]

  • 5. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.
    De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S, Sudan D, Fung J, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Witte S, Jiang H, Hexham JM, Junge G, H2304 Study Group.
    Am J Transplant; 2012 Nov; 12(11):3008-20. PubMed ID: 22882750
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials.
    Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, Nevens F, Suh KS, Fischer L, Jin Joo D, Fung J, Joh JW, Kaido T, Grant D, Meier M, Rauer B, Sips C, Kaneko S, Levy G.
    Transplantation; 2021 Jul 01; 105(7):1564-1575. PubMed ID: 33741847
    [Abstract] [Full Text] [Related]

  • 7. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
    Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux G, Leroy V, Hardwigsen J, Gharbi H, Masson C, Tindel M, Conti F.
    Liver Transpl; 2019 Dec 01; 25(12):1822-1832. PubMed ID: 31631501
    [Abstract] [Full Text] [Related]

  • 8. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
    Mocchegiani F, Montalti R, Nicolini D, Svegliati Baroni G, Benedetti A, Risaliti A, Vivarelli M.
    Ann Transplant; 2014 Oct 27; 19():545-50. PubMed ID: 25347718
    [Abstract] [Full Text] [Related]

  • 9. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.
    Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S, Sudan D, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Dong G, Lopez PM, Fung J, Junge G, H2304 Study Group.
    Am J Transplant; 2013 Jul 27; 13(7):1734-45. PubMed ID: 23714399
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M, Higashiyama H, Fukasawa Y, Itoh Y, Tamaki T.
    Nephrology (Carlton); 2015 Jul 27; 20 Suppl 2():58-60. PubMed ID: 26031588
    [Abstract] [Full Text] [Related]

  • 11. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B, Schemmer P, Braun F, Dworak M, Wimmer P, Schlitt H.
    Trials; 2015 Mar 26; 16():118. PubMed ID: 25873064
    [Abstract] [Full Text] [Related]

  • 12. Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial.
    Nashan B, Schemmer P, Braun F, Schlitt HJ, Pascher A, Klein CG, Neumann UP, Kroeger I, Wimmer P, Hephaistos Study Group.
    Liver Transpl; 2022 Jun 26; 28(6):998-1010. PubMed ID: 34525259
    [Abstract] [Full Text] [Related]

  • 13. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Jun 26; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 14. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
    Manzia TM, Angelico R, Toti L, Grimaldi C, Sforza D, Vella I, Tariciotti L, Lenci I, Breshanaj G, Baiocchi L, Tisone G.
    Transplant Proc; 2018 Jun 26; 50(1):175-183. PubMed ID: 29407305
    [Abstract] [Full Text] [Related]

  • 15. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar 26; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May 26; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 17. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D.
    Am J Transplant; 2017 Sep 26; 17(9):2363-2371. PubMed ID: 28141897
    [Abstract] [Full Text] [Related]

  • 18. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.
    Gómez-Bravo M, Prieto Castillo M, Navasa M, Sánchez-Antolín G, Lladó L, Otero A, Serrano T, Jiménez Romero C, García González M, Valdivieso A, González-Diéguez ML, de la Mata M, Pons JA, Salcedo M, Rodrigo JM, Cuervas-Mons V, González Rodríguez A, Caralt M, Pardo F, Varo Pérez E, Crespo G, Rubin Á, Guilera M, Aldea A, Santoyo J.
    Rev Esp Enferm Dig; 2022 Jun 26; 114(6):335-342. PubMed ID: 35469409
    [Abstract] [Full Text] [Related]

  • 19. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
    Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjær H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F.
    Transplantation; 2017 Nov 26; 101(11):2793-2800. PubMed ID: 28230646
    [Abstract] [Full Text] [Related]

  • 20. Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study.
    Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux GP, Hardwigsen J, Benkhatar Y, Derquenne F, Conti F.
    Liver Int; 2022 Nov 26; 42(11):2513-2523. PubMed ID: 35962772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.